Tertius News is an AI-native newsroom: an AI model reads the linked source articles below and extracts what each outlet reported, so you can compare their coverage side by side. How this works →

New information became available — this story may be updated shortly.

Symbiotec Pharmalab lists flat in muted debut, stock later climbs after weak open

Symbiotec Pharmalab made a muted stock market debut on Tuesday, listing nearly 1% lower on the BSE and at par on the NSE, below grey market expectations of an 18-19% gain. The IPO was subscribed 71.26 times, and the company is raising funds through a fresh issue and an offer for sale.

By Tertius News AI Desk 2 distinct · 3 mastheads · 3 articles Version 1 Coverage Sep 1, 2026 Published 59m ago

Symbiotec Pharmalab lists flat in muted debut, stock later climbs after weak open

Shares of pharma and biotech company Symbiotec Pharmalab Ltd began trading on the stock exchanges on Tuesday with a muted debut, opening nearly 1% lower on the BSE and at par on the NSE against the issue price of ₹988.

On the BSE, the stock opened at ₹978.20, down 0.99% from the issue price. However, by later trade it recovered to ₹1,074.05, up 8.70%. On the NSE, the shares listed unchanged at ₹988 and later climbed 9.65% to ₹1,083.40.

The listing was well below grey market expectations, which had indicated a listing gain of around 18-19% for IPO investors, according to Business Standard.

IPO details and subscription

The initial public offering of Symbiotec Pharmalab was subscribed 71.26 times, with bids for 93,52,49,700 shares against 1,31,24,929 shares on offer, as reported by Business Standard. The category for qualified institutional buyers (QIBs) received 172.03 times subscription, the non-institutional investor (NII) portion was subscribed 73.63 times, and the retail investor portion received 12.96 times subscription.

The IPO had a price band of ₹938-988 per equity share, valuing the company around ₹6,350 crore at the upper limit. The company's market capitalisation stood at ₹6,285.53 crore, according to BSE data.

The IPO was a combination of a fresh issue of shares worth up to ₹150 crore and an offer for sale (OFS) component amounting to ₹1,607 crore. As part of the OFS, promoter Satwani Holdings LLP and investors Rosewood Investments and India Business Excellence Fund III will offload shares.

Proceeds from the fresh issue will be used for debt payment and general corporate purposes, the company said.

Company background

Symbiotec Pharmalab is an Indore-based, research and development-driven pharmaceutical and biotechnology company with capabilities across three platforms: organic chemistry, biotechnology, and complex injectables.

How each outlet told it

A framing line is our reading of that outlet's own text — an interpretation, not a quotation and not a fact we assert. Check it against what the outlet published.

Business Standard

Framing: Marks the debut as 'tepid' and highlights that it listed at par with the IPO price. — Negative tone, emphasizing the disappointment relative to expectations.

as of Sep 1, 2026, 6:17 AM UTC

Facts Included:

The listing of Symbiotec Pharmalab was well below GMP expectations, which had indicated a listing gain of around 18-19 per cent for IPO investors.
Symbiotec Pharmalab share price today: Shares of pharma and biotech company Symbiotec Pharmalab made a tepid debut on the stock exchanges on Tuesday, with the stock listing largely in line with its issue price of ₹988.
On the NSE, the shares listed at ₹988, unchanged from the issue price.
The IPO received bids for 93,52,49,700 shares against 1,31,24,929 shares on offer.
The IPO had a price band of ₹938-988 per equity share, valuing the company around ₹6,350 crore at the upper limit.
The IPO had a fresh issue of shares worth up to ₹150 crore and an offer for sale (OFS) component amounting to ₹1,607 crore.

Read the source article →

Outlook Business

Framing: Market debut was muted but shares bounced back later — Neutral factual reporting, with a focus on price movements and IPO details.

as of Sep 1, 2026, 7:16 AM UTC

Facts Included:

Shares of pharma and biotech company Symbiotec Pharmalab Ltd on Tuesday made a muted market debut, listing nearly 1% lower on the BSE, against the issue price of ₹988.
At the NSE, the stock listed at par with the issue price at ₹988.
The IPO was a combination of a fresh issue of shares worth up to ₹150 crore and an Offer For Sale (OFS) component amounting to ₹1,607 crore.

Read the source article →

The Hindu Business Line

Framing: Emphasizes a muted debut but later gain

as of Sep 1, 2026, 8:17 AM UTC

Facts Included:

Symbiotec Pharmalab Ltd listed nearly 1 per cent lower on the BSE, against the issue price of Rs 988.
At the NSE, the stock listed at par with the issue price at Rs 988.
The IPO was a combination of a fresh issue of shares worth up to Rs 150 crore and an OFS component amounting to Rs 1,607 crore.
The company's IPO price band was Rs 938-988 per equity share.
Proceeds of the fresh issue will be used for debt payment and general corporate purposes.
The Indore-based Symbiotec is a research and development-driven pharmaceutical and biotechnology company with capabilities across three platforms -- organic chemistry, biotechnology, and complex injectables.
It's a global leader in corticosteroid and steroidal hormone active pharmaceutical ingredients (APIs).

Read the source article →

What was claimed, and who backed it

AI-extracted; can misattribute a claim — see Methodology.

Each row is one claim, attributed to the outlet whose wording states it most clearly. Confidence rates how directly the source text states the claim — explicit and unhedged rates high; hedged, pieced-together, or internally inconsistent statements rate lower. It does not measure whether the claim is true. Status is Contested when two claims on this page negate each other; otherwise it counts the distinct outlets we found asserting that specific claim — so a single-source claim can still show high confidence, and a multi-source claim can show medium. Every one of those outlets is named beside the status, so you can check the count against the list. For claims extracted before we began storing that list, the row says so: it names the outlet the claim is quoted from and states that we have not recorded which outlets backed it. Outlets wrote at different times, so a figure that evolves — a casualty count, for example — can legitimately differ between rows; check the "as of" time next to each claim's source.

Claim	Confidence	Status
ClaimShares of Symbiotec Pharmalab Ltd made a muted market debut, listing nearly 1% lower on the BSE, against the issue price of ₹988.	ConfidenceHigh	StatusMulti-source (2 outlets · 2 distinct) via Outlook Business as of Sep 1, 2026, 7:16 AM UTC, Business Standard as of Sep 1, 2026, 6:17 AM UTC
ClaimAt the NSE, the stock listed at par with the issue price at ₹988.	ConfidenceHigh	StatusSingle-source via Outlook Business as of Sep 1, 2026, 7:16 AM UTC
ClaimThe IPO was a combination of a fresh issue of shares worth up to ₹150 crore and an Offer For Sale (OFS) component amounting to ₹1,607 crore.	ConfidenceHigh	StatusMulti-source (2 outlets · 2 distinct) via Outlook Business as of Sep 1, 2026, 7:16 AM UTC, Business Standard as of Sep 1, 2026, 6:17 AM UTC
ClaimProceeds of the fresh issue will be used for debt payment and general corporate purposes.	ConfidenceHigh	StatusMulti-source (2 outlets · 2 distinct) via Outlook Business as of Sep 1, 2026, 7:16 AM UTC, Business Standard as of Sep 1, 2026, 6:17 AM UTC
ClaimThe listing was well below GMP expectations, which had indicated a listing gain of around 18-19 per cent for IPO investors.	ConfidenceMedium	StatusSingle-source via Business Standard as of Sep 1, 2026, 6:17 AM UTC
ClaimThe IPO was subscribed 71.26 times, with bids for 93,52,49,700 shares against 1,31,24,929 shares on offer.	ConfidenceHigh	StatusSingle-source via Business Standard as of Sep 1, 2026, 6:17 AM UTC
ClaimThe IPO had a price band of ₹938-988 per equity share, valuing the company around ₹6,350 crore at the upper limit.	ConfidenceHigh	StatusSingle-source via Business Standard as of Sep 1, 2026, 6:17 AM UTC
ClaimThe company's market capitalisation stood at ₹6,285.53 crore, according to BSE data.	ConfidenceMedium	StatusSingle-source via Business Standard as of Sep 1, 2026, 6:17 AM UTC
ClaimThe initial public offering of Symbiotec Pharmalab was subscribed 71.26 times.	ConfidenceHigh	StatusMulti-source (2 outlets · 2 distinct) via Business Standard as of Sep 1, 2026, 6:17 AM UTC, Outlook Business as of Sep 1, 2026, 7:16 AM UTC
ClaimAs part of the OFS, promoter Satwani Holdings LLP and investors Rosewood Investments and India Business Excellence Fund III will offload shares.	ConfidenceHigh	StatusSingle-source via Business Standard as of Sep 1, 2026, 6:17 AM UTC
ClaimSymbiotec Pharmalab is a research and development-driven pharmaceutical and biotechnology company with platforms in organic chemistry, biotechnology, and complex injectables.	ConfidenceHigh	StatusSingle-source via Business Standard as of Sep 1, 2026, 6:17 AM UTC

Transparency & Audit Trail

2 distinct · 3 mastheads · 3 articles consulted: Business Standard, Outlook Business, The Hindu Business Line 11 claims extracted Version 1 Written 2026-09-01